ESR1 and breast cancer: In this regard, a steroid structure based, highly Selective Estrogen Receptor Degrader (SERD) like fulvestrant, inhibit estrogen signaling process through the ER by acting as an antagonist to the estradiol binding to the ER and decreasing the ER level in breast cancer cells [3–7].